Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma

Journal of Clinical Microbiology

Volumn 42, Issue 8, 2004, Pages 3670-3674

  Ellis, Giovanina M ^a   Mahalanabis, Madhumita ^a,b   Beck, Ingrid A ^a   Pepper, Gregory ^b   Wright, Amy ^b   Hamilton, Shannon ^b   Holte, Sarah ^c   Naugler, Willscott E ^a,e   Pawluk, Diane M ^a   Li, Chung Chen ^a   Frenkel, Lisa M ^a,b,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NONE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; OLIGONUCLEOTIDE;

AMPLICON; ARTICLE; ASSAY; CONSENSUS SEQUENCE; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE LIGATION ASSAY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VALIDATION PROCESS; VIROGENESIS; VIRUS DETECTION; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BASE SEQUENCE; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 3843061329     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.8.3670-3674.2004     Document Type: Article

References (30)

1. Alexander, C. S., W. Dong, K. Chan, N. Jahnke, M. V. O'Shaughnessy, T. Mo, M. A. Piaseczny, J. S. Montaner, and P. R. Harrigan. 2001. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 15:601-607.
2. Balotta, C., A. Berlusconi, A. Pan, M. Violin, C. Riva, M. C. Colombo, A. Gori, L. Papagno, S. Corvasce, R. Mazzucchelli, G. Facchi, R. Velleca, G. Saporetti, M. Galli, S. Rusconi, and M. Moroni. 2000. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir. Ther. 5:7-14.
3. Bardeguez, A. D., D. E. Shapiro, L. M. Mofenson, R. Coombs, L. M. Frenkel, M. G. Fowler, S. Huang, R. S. Sperling, B. Cunningham, J. Gandia, R. Maupin, C. D. Zorrilla, T. Jones, M. J. O'Sullivan, and the Pediatric AIDS Clinical Trials Group 288 Protocol Team. 2003. Effect of cessation of zidovuvudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 32:170-181.
4. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, M. L. Hoover, M. A. Winters, S. B. Mannheimer, M. A. Thompson, D. I. Abrams, B. J. Brizz, J. P. Ioannidis, and T. C. Merigan. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14:F83-F93.
5. Beck, I. A., M. Mabalanabis, G. Pepper, A. Wright, S. Hamilton, E. Langston, and L. M. Frenkel. 2002. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J. Clin. Microbiol. 40:1413-1419.
6. Birk, M., V. Svedbem, and A. Sönnerborg. 2001. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 15:1359-1368.
7. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
8. Chun, T. W., R. T. Davey Jr., M. Ostrowski, J. Shawn Justement, D. Engel, J. I. Mullins, and A. S. Fauci. 2000. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-761.
9. Cingolani, A., A. Antinori, M. G. Rizzo, R. Murri, A. Ammassari, F. Baldini, S. Di Giambenedetto, R. Cauda, and A. De Luca. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16:369-379.
10. Cohen, C. J., S. Hunt, M. Sension, C. Farthing, M. Conant, S. Jacobson, J. Nadler, W. Verbiest, K. Hertogs, M. Ames, A. R. Rinehart, N. M. Graham, and VIRA3001 Study Team. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579-588.
11. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
12. Durant, J., P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C. A. Boucher, J. M. Schapiro, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
13. Eastman, P. S., D. E. Shapiro, R. W. Coombs, L. M. Frenkel, G. D. McSherry, P. Britto, S. A. Herman, and R. S. Sperling. 1998. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J. Infect. Dis. 177:557-564.
14. Edelstein, R. E., E. A. Nickerson, V. O. Tobe, L. A. Manns-Arcuino, and L. M. Frenkel. 1998. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J. Clin. Microbiol. 36:569-572.
15. Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petropoulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
16. Hermankova, M., S. C. Ray, C. Ruff, M. Powell-Davis, R. Ingersoll, R. T. D'Aquila, T. C. Quinn, J. D. Siliciano, R. F. Siliciano, and D. Persaud. 2001. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 286:196-207.
17. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel. JAMA 283:2417-2426.
18. Izopet, J., P. Massip, C. Souyris, K. Sandres, B. Puissant, M. Obadia, C. Pasquier, E. Bonnet, B. Marchou, and J. Puel. 2000. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14:2247-2255.
19. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
20. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
21. Martinez-Picado, J., M. P. DePasquale, N. Kartsonis, G. J. Hanna, J. Wong, D. Finzi, E. Rosenberg, H. F. Gunthard, L. Sutton, A. Savara, C. J. Petropoulos, N. Hellmann, B. D. Walker, D. D. Richman, R. Siliciano, and R. T. D'Aquila. 2000. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97:10948-10953.
22. Meynard, J. L., M. Vray, L. Morand-Joubert, E. Race, D. Descamps, G. Peytavin, S. Matheron, C. Lamotte, S. Guiramand, D. Costagliola, F. Brun-Vezinet, F. Clavel, P. M. Girard, and the Narval Trial Group. 2002. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16:727-736.
23. Schmit, J. C., L. Ruiz, L. Stuyver, K. Van Laethem, I. Vanderlinden, T. Puig, R. Rossau, J. Desmyter, E. De Clercq, B. Clotet, and A. M. Vandamme. 1998. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J. Virol. Methods. 73:77-82.
24. Schuurman, R., D. Brambilla, T. de Groot, D. Huang, S. Land, J. Bremer, I. Benders, C. A. Boucher, and the ENVA Working Group. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir. 18:243-248.
25. Servais, J., C. Lambert, E. Fontaine, J. M. Plesseria, I. Robert, V. Arendt, T. Staub, F. Schneider, R. Hemmer, G. Burtonboy, and J. C. Schmit. 2001. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J. Clin. Microbiol. 39:454-459.
26. Servais, J., C. Lambert, J. M. Plesseria, E. Fontaine, I. Robert, V. Arendt, T. Staub, R. Hemmer, F. Schneider, and J. C. Schmit. 2002. Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy. Antimicrob. Agents Chemother. 46: 1928-1933.
27. Stuyver, L., A. Wyseur, A. Rombout, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. F. Schinazi, and R. Rossau. 1997. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:284-291.
28. Van Laethem, K., K. Van Vaerenbergh, J. C. Schmit, S. Sprecher, P. Hermans, V. De Vroey, R. Schuurman, T. Harrer, M. Witvrouw, E. Van Wijngaerden, L Stuyver, M. Van Ranst, J. Desmyter, E. De Clercq, and A. M. Vandamme. 1999. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J. Acquir. Immune Defic. Syndr. 22:107-118.
29. Van Vaerenbergh, K., L. Debaisieux, N. De Cabooter, C. Declereq, K. Desmet, K. Fransen, B. Maes, D. Marissens, K. Miller, G. Muyldermans, S. Sprecher, L. Stuyver, D. Vaira, C. Verhofstede, G. Zissis, M. Van Ranst, E. De Clereq, J. Desmyter, and A. M. Vandamme. 2001. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antivir. Ther. 6:63-70.
30. Villahermosa, M. L., I. Beck, L. Perez-Alvarez, G. Contreras, L. M. Frenkel, S. Osmanov, E. V. de Parga, E. Delgado, N. Manjon, M. T. Cuevas, M. M. Thomson, L. Medrano, and R. Najera. 2001. Detection and quantification of multiple drug resistance-associated mutation in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J. Hum. Virol. 4:238-248.